Copyright © 2001 by the European Society of Cardiology.
Ventricular assist device in severe heart failure. Effects on cytokines, complement and body weight
a Department of Academic Cardiology, Castle Hill Hospital, Cottingham, Hull, U.K.
b Department of Thoracic and Cardiovascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany
c Franz-Volhard-Klinik (Charité, Berlin-Buch) at MDC Berlin, Germany
d Department of Cardiac Medicine, National Heart and Lung Institute, London, U.K.
revised March 6, 2001; accepted March 14, 2001
Abstract
Aims Inflammatory and immune activation and body wasting are important features of end-stage chronic heart failure. It is not known whether restoration of cardiac output by assist device implantation can improve these abnormalities.
Methods We studied 48 patients (39 males; age 45±2 years) with NYHA class IV heart failure. All patients underwent ventricular assist device implantation for end-stage heart failure as a bridge to cardiac transplantation. Plasma levels of tumour necrosis factor 
, and its receptors, interleukin-6, elastase, activated complement, and soluble CD14 receptors were measured at the time of operation and in survivors at 1 week (n=46), 40 days (n=35) and 90 days (n=26). Follow-up was for a minimum of 1 year.
Results One-year survival was 35% (95% CI: 22–49%). Body mass index was the only predictor of survival (body mass index >25 (n=16); survival 63 (39–86)%; body mass index <25 (n=32); survival 22 (7·5–36)%: P=0·003). Tumour necrosis factor fell from 9·66±1·33pg.ml–1to 4·2±1·0 at 1 week (P=0·008), but returned to pre-operative levels at 90 days. Interleukin-6, activated complement and elastase fell progressively to 40 days, but were rising at 90 days. There was no change in tumour necrosis factor receptor. There was a gradual rise in CD14 (3·99±0·15µg.ml–1at baseline, 5·02±0·39 at 90 days, P=0·006). After surgery, body weight fell from 80±2 to 73±2kg by 1 month (P<0·001) and to 72±2kg at 90 days.
Conclusions Ventricular assist device implantation results in a short-term fall in tumour necrosis factor and interleukin-6, but no change in CD14 or tumour necrosis factor receptor, suggesting that the pathophysiological process resulting in inflammation was not altered by left ventricular assist device implantation. Low body mass index is related to poor outcome after assist device implantation, and no weight gain.
Key Words: Chronic heart failure, ventricular assist device, cytokines, tumour necrosis factor
f1 Correspondence: Dr A. L. Clark, Department of Academic Cardiology, Castle Hill Hospital, Castle Road, Cottingham, Hull, HU16 5JQ, U.K.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  B. Vrtovec, R. Radovancevic, R. M. Delgado, B. Radovancevic, A. W. Bracey, I. D. Gregoric, and O.H. Frazier Significance of anaemia in patients with advanced heart failure receiving long-term mechanical circulatory support Eur J Heart Fail, October 1, 2009; 11(10): 1000 - 1004. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Musci, A. Loforte, E. V. Potapov, T. Krabatsch, Y. Weng, M. Pasic, and R. Hetzer Body Mass Index and Outcome After Ventricular Assist Device Placement Ann. Thorac. Surg., October 1, 2008; 86(4): 1236 - 1242. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M. Kimball, M. Flattery, F. McDougan, and V. Kasirajan Cellular Immunity Impaired Among Patients on Left Ventricular Assist Device for 6 Months Ann. Thorac. Surg., May 1, 2008; 85(5): 1656 - 1661. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. L. Clark, C. Knosalla, E. Birks, M. Loebe, C. H. Davos, S. Tsang, A. Negassa, M. Yacoub, R. Hetzer, A. J.S. Coats, et al. Heart transplantation in heart failure: The prognostic importance of body mass index at time of surgery and subsequent weight changes Eur J Heart Fail, August 1, 2007; 9(8): 839 - 844. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M Vanderheyden, W J Paulus, M Voss, P Knuefermann, N Sivasubramanian, D Mann, and G Baumgarten Myocardial cytokine gene expression is higher in aortic stenosis than in idiopathic dilated cardiomyopathy Heart, July 1, 2005; 91(7): 926 - 931. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Langer, R. Schramm, M. Bauer, D. Tscholl, T. Kunihara, and H.-J. Schafers Cytokine Response to Pulmonary Thromboendarterectomy Chest, July 1, 2004; 126(1): 135 - 141. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. G. F. Cleland and A. L. Clark Delivering the cumulative benefits of triple therapy to improve outcomes in heart failure: Too many cooks will spoil the broth J. Am. Coll. Cardiol., October 1, 2003; 42(7): 1234 - 1237. [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Chen, S. Park, Y. Li, E. Missov, M. Hou, X. Han, J. L. Hall, L. W. Miller, and R. J. Bache Alterations of gene expression in failing myocardium following left ventricular assist device support Physiol Genomics, August 15, 2003; 14(3): 251 - 260. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Beholz, H. Hotz, J. Grosse, and W. Konertz Biventricular assist device in extreme anorexia nervosa Interactive CardioVascular and Thoracic Surgery, September 1, 2002; 1(1): 35 - 37. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Chatterjee Refractory heart failure--drugs and devices Eur. Heart J., December 2, 2001; 22(24): 2227 - 2230. [PDF]
|
|